Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31

Go back to Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31

Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital

February 11, 2022 7:21 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.

The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More